Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience

Basit Öğe Kaydı
dc.authorid, Jamshid/0000-0002-5823-1704
dc.contributor.authorHamdard, Jamshid
dc.contributor.authorBilici, Ahmet
dc.contributor.authorSakin, Abdullah
dc.contributor.authorKahraman, Seda
dc.contributor.authorYasin, Ayse Irem
dc.contributor.authorKalaci, Ender
dc.contributor.authorGokmen, Ivo
dc.date.accessioned2024-06-12T11:02:30Z
dc.date.available2024-06-12T11:02:30Z
dc.date.issued2024
dc.departmentTrakya Üniversitesien_US
dc.description.abstractWe evaluated the incidence, clinicopathological features, prognostic factors, progression-free survival (PFS) and overall survival (OS) of patients with gastric cancer and bone metastases. The medical records of 110 patients with bone metastases were retrospectively analyzed. In our study, the incidence of bone metastases was 3.2%. The median patient age was 60 years. A total of 68 (61.8%) patients exhibited synchronous metastases, and 42 (38.2%) patients developed metachronous metastases. Alkaline phosphatase (ALP) levels were high in 54 (49%) patients. At the median follow-up time of 9.8 months, median PFS and OS times were 4.7 and 6.3 months, respectively. The median interval from the diagnosis to bone metastases was 9.3 months. Univariate analysis showed that Eastern Cooperative Oncology Group Performance Status (ECOG PS) >= 2, stage at diagnosis, time of metastases, number of metastases, presence of extraskeletal metastases, use of zoledronic acid treatment, palliative chemotherapy post-bone metastases and radiotherapy to bone metastases were significant prognostic indicators for PFS. Additionally, ECOG PS >= 2, stage at diagnosis, time of metastases, number of metastases, presence of extraskeletal metastases, zoledronic acid treatment, palliative chemotherapy post-bone metastases, and radiotherapy to bone metastases significantly influenced OS. Moreover, in multivariate analysis, ECOG PS, time of metastases, presence of extra-bone metastases, and the use of palliative chemotherapy after bone metastases were found to be independent prognostic factors for PFS. Moreover, ECOG PS, time of metastases, and use of palliative chemotherapy after bone metastases were significantly independent prognostic indicators for OS. Our findings show that the presence of synchronous metastases, use of palliative chemotherapy, use of zoledronic acid after bone metastases, and ALP level within the normal range were significantly associated with prolonged OS in gastric cancer patients with bone metastases.en_US
dc.identifier.doi10.1080/1120009X.2024.2358458
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.pmid38803194en_US
dc.identifier.scopus2-s2.0-85194589154en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1080/1120009X.2024.2358458
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21292
dc.identifier.wosWOS:001233756200001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal Of Chemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGastric Canceren_US
dc.subjectBone Metastasesen_US
dc.subjectProgression-Free Survivalen_US
dc.subjectOverall Survivalen_US
dc.subjectZoledronic Aciden_US
dc.subjectDouble-Blinden_US
dc.titleCharacteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu